Anti-angiogenic inhibition of tumor growth by systemic delivery of PEI-g-PEG-RGD/pCMV-sFlt-1 complexes in tumor-bearing mice

Kim, Won Jong; Yockman, James W.; Jeong, Ji Hoon; Christensen, Lane V.; Lee, Minhyung; Kim, Yong Hee; Kim, Sung Wan

doi:10.1016/j.jconrel.2006.05.029

Cited by 83 publications

(53 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Utilizing the improved and selective binding of cyclic Arg-Gly-Asp (RGD) peptide with anb3 integrin, which is overexpressed in a wide range of tumors, RGD containing polymeric formulation are widely used in tumor targeted gene delivery (Kim et al, 2005(Kim et al, , 2006a. RGD labeled chitosan nanoparticles was fabricated for targeted silencing of multiple growth-promoting genes (Han et al, 2010).…”

Section: Chitosanmentioning

confidence: 99%

Polymers in Small-Interfering RNA Delivery

Singha

Namgung

Kim

2011

Nucleic Acid Therapeutics

Self Cite

181

111

View full text Add to dashboard Cite

This review will cover the current strategies that are being adopted to efficiently deliver small interfering RNA using nonviral vectors, including the use of polymers such as polyethylenimine, poly(lactic-co-glycolic acid), polypeptides, chitosan, cyclodextrin, dendrimers, and polymers-containing different nanoparticles. The article will provide a brief and concise account of underlying principle of these polymeric vectors and their structural and functional modifications which were intended to serve different purposes to affect efficient therapeutic outcome of small-interfering RNA delivery. The modifications of these polymeric vectors will be discussed with reference to stimuli-responsiveness, target specific delivery, and incorporation of nanoconstructs such as carbon nanotubes, gold nanoparticles, and silica nanoparticles. The emergence of small-interfering RNA as the potential therapeutic agent and its mode of action will also be mentioned in a nutshell.

show abstract

Section: Chitosanmentioning

confidence: 99%

Polymers in Small-Interfering RNA Delivery

Singha

Namgung

Kim

2011

Nucleic Acid Therapeutics

Self Cite

181

111

View full text Add to dashboard Cite

show abstract

“…38 Kim et al [39][40][41] prepared PEI-g-PEG-RGD copolymer by conjugating a anb3/anb5 integrin-binding RGD peptide (ACDCRGDCFC, dicyclic form) to a cationic polymer (PEI), with a hydrophilic polyethylene glycol (PEG) spacer (Figure 1a). [39][40][41] The successful complexation of plasmid DNA (pDNA) with the synthetic PEI-g-PEG-RGD polymer was confirmed by agarose gel electrophoresis. Although the size of PEI/pDNA complexes depended on the N/P ratio (the ratio of concentrations of total nitrogen atoms (N) of polycation to the phosphate groups (P) of DNA), the size of PEI-g-PEG-RGD/pDNA complexes was proven to be less affected by the N/P ratio.…”

Section: Rgd-functionalized Polymer-based Vectorsmentioning

confidence: 99%

“…40 In vivo biodistribution of the PEI-g-PEG-RGD vector was studied in a colon cancer animal model (CT-26 mouse colon adenocarcinoma). 41 A therapeutic gene, pCMV-sFlt-1 encoding soluble VEGF receptor 1 as a VEGF antagonist was complexed with either PEI-g-PEG-RGD or PEI-g-PEG, which was then administrated into subcutaneous tumor-bearing mice by i.v. injection.…”

Section: Rgd-functionalized Polymer-based Vectorsmentioning

confidence: 99%

See 1 more Smart Citation

A review of RGD-functionalized nonviral gene delivery vectors for cancer therapy

et al. 2012

View full text Add to dashboard Cite

The development of effective treatments that enable many patients suffering from cancer to be successfully cured is highly demanded. Angiogenesis, which is a process for the formation of new capillary blood vessels, has a crucial role in solid tumor progression and the development of metastasis. Antiangiogenic therapy designed to prevent tumor angiogenesis, thereby arresting the growth or spread of tumors, has emerged as a non-invasive and safe option for cancer treatment. Due to the fact that integrin receptors are overexpressed on the surface of angiogenic endothelial cells, various strategies have been made to develop targeted delivery systems for cancer gene therapy utilizing integrin-targeting peptides with an exposed arginine-glycine-aspartate (RGD) sequence. The aim of this review is to summarize the progress and prospect of RGD-functionalized nonviral vectors toward targeted delivery of genetic materials in order to achieve an efficient therapeutic outcome for cancer gene therapy, including antiangiogenic therapy.

show abstract

“…cRGD peptide selectively recognizes a v b 3 and a v b 5 integrins, 27 and previous studies showed that a v b 3 and a v b 5 are abundantly expressed on endothelial cells and smooth muscle cells in vascular lesions. [28][29][30] PEG-PAsp(DET) micelles installed with cRGD (cRGD-PEG-PAsp (DET) micelles) were applied to endothelial cells and vascular smooth muscle cells in vitro and also to rat carotid artery with neointimal hyperplasia, and the efficacy of gene transfer was evaluated as compared with that of ligand-free PEG-PAsp(DET) micelles. (Figures 2a and b).…”

Section: Introductionmentioning

confidence: 99%

Impact of polyplex micelles installed with cyclic RGD peptide as ligand on gene delivery to vascular lesions

et al. 2011

View full text Add to dashboard Cite

Gene therapy is expected to open a new strategy for the treatment of refractory vascular diseases, so the development of appropriate gene vectors for vascular lesions is needed. To realize this requirement with a non-viral approach, cyclo(RGDfK) peptide (cRGD) was introduced to block copolymer, poly(ethylene glycol)-block-polycation carrying ethylenediamine units (PEG-PAsp(DET)). cRGD recognizes a v b 3 and a v b 5 integrins, which are abundantly expressed in vascular lesions. cRGDconjugated PEG-PAsp(DET) (cRGD-PEG-PAsp(DET)) formed polyplex micelles through complexation with plasmid DNA (pDNA) and the cRGD-PEG-PAsp(DET) micelles achieved significantly more efficient gene expression and cellular uptake as compared with PEG-PAsp(DET) micelles in endothelial cells and vascular smooth muscle cells. Intracellular tracking of pDNA showed that cRGD-PEG-PAsp(DET) micelles were internalized via caveolae-mediated endocytosis, which is associated with a pathway avoiding lysosomal degradation and that, PEG-PAsp(DET) micelles were transported to acidic endosomes and lysosomes via clathrin-mediated endocytosis. Further, in vivo evaluation in rat carotid artery with a neointimal lesion revealed that cRGD-PEGPAsp(DET) micelles realized sustained gene expression, whereas PEG-PAsp(DET) micelles facilitated rapid, but transient gene expression. These findings suggest that introduction of cRGD to polyplex micelles might create novel and useful functions for gene transfer and contribute to the establishment of efficient gene therapy for vascular diseases.

show abstract

Anti-angiogenic inhibition of tumor growth by systemic delivery of PEI-g-PEG-RGD/pCMV-sFlt-1 complexes in tumor-bearing mice

Cited by 83 publications

References 37 publications

Polymers in Small-Interfering RNA Delivery

Polymers in Small-Interfering RNA Delivery

A review of RGD-functionalized nonviral gene delivery vectors for cancer therapy

Impact of polyplex micelles installed with cyclic RGD peptide as ligand on gene delivery to vascular lesions

Contact Info

Product

Resources

About